Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
Pacira BioSciences (PCRX) has confirmed receiving director nominations from DOMA Perpetual Capital Management for its 2025 Annual Meeting of Stockholders. DOMA has proposed three candidates for election to Pacira's Board of Directors.
In response, Pacira stated that its Board and management team are implementing actions to enhance shareholder value, including a recently completed comprehensive portfolio review and the establishment of their '5x30 plan'. The company's Nominating, Governance and Sustainability Committee will evaluate DOMA's proposed candidates as part of their standard review process.
The Board will present its formal recommendation regarding director nominees in the upcoming definitive proxy statement. No immediate shareholder action is required, and the 2025 Annual Meeting date has not been announced. Evercore and Wachtell, Lipton, Rosen & Katz are serving as financial and legal advisors respectively.
Pacira BioSciences (PCRX) ha confermato di aver ricevuto le nomination per i direttori da parte di DOMA Perpetual Capital Management in vista della sua Assemblea Annuale degli Azionisti del 2025. DOMA ha proposto tre candidati per l'elezione nel Consiglio di Amministrazione di Pacira.
In risposta, Pacira ha dichiarato che il suo Consiglio e il team di gestione stanno attuando azioni per migliorare il valore per gli azionisti, inclusa una revisione completa del portafoglio recentemente completata e l'istituzione del loro 'piano 5x30'. Il Comitato per le Nomine, la Governance e la Sostenibilità dell'azienda valuterà i candidati proposti da DOMA come parte del loro processo di revisione standard.
Il Consiglio presenterà la sua raccomandazione formale riguardo ai candidati per i direttori nella prossima dichiarazione di delega definitiva. Non è richiesta alcuna azione immediata da parte degli azionisti, e la data dell'Assemblea Annuale del 2025 non è stata annunciata. Evercore e Wachtell, Lipton, Rosen & Katz stanno fungendo rispettivamente da consulenti finanziari e legali.
Pacira BioSciences (PCRX) ha confirmado haber recibido nominaciones para directores de DOMA Perpetual Capital Management para su Junta Anual de Accionistas de 2025. DOMA ha propuesto tres candidatos para la elección al Consejo de Administración de Pacira.
En respuesta, Pacira declaró que su Consejo y equipo de gestión están implementando acciones para aumentar el valor para los accionistas, incluyendo una revisión integral del portafolio recientemente completada y el establecimiento de su 'plan 5x30'. El Comité de Nominaciones, Gobernanza y Sostenibilidad de la empresa evaluará a los candidatos propuestos por DOMA como parte de su proceso de revisión estándar.
El Consejo presentará su recomendación formal sobre los nominados a directores en la próxima declaración de poder definitiva. No se requiere ninguna acción inmediata por parte de los accionistas, y la fecha de la Junta Anual de 2025 no ha sido anunciada. Evercore y Wachtell, Lipton, Rosen & Katz están actuando como asesores financieros y legales, respectivamente.
Pacira BioSciences (PCRX)는 DOMA Perpetual Capital Management로부터 2025년 주주총회를 위한 이사 후보 추천을 받았다고 확인했습니다. DOMA는 Pacira의 이사회에 선출할 세 명의 후보를 제안했습니다.
이에 대해 Pacira는 이사회와 경영진이 주주 가치를 향상시키기 위한 조치를 시행하고 있으며, 최근에 완료된 포트폴리오 종합 검토와 '5x30 계획' 수립을 포함한다고 밝혔습니다. 회사의 추천, 거버넌스 및 지속 가능성 위원회는 DOMA가 제안한 후보를 표준 검토 과정의 일환으로 평가할 것입니다.
이사회는 다음 공식 위임장 성명서에서 이사 후보에 대한 공식 권고를 발표할 것입니다. 주주가 즉각적으로 조치를 취할 필요는 없으며, 2025년 주주총회 날짜는 아직 발표되지 않았습니다. Evercore와 Wachtell, Lipton, Rosen & Katz는 각각 재무 및 법률 자문 역할을 하고 있습니다.
Pacira BioSciences (PCRX) a confirmé avoir reçu des nominations de directeurs de DOMA Perpetual Capital Management pour sa Réunion Annuelle des Actionnaires de 2025. DOMA a proposé trois candidats pour l'élection au Conseil d'Administration de Pacira.
En réponse, Pacira a déclaré que son Conseil et son équipe de direction mettent en œuvre des actions pour accroître la valeur pour les actionnaires, y compris un examen complet du portefeuille récemment achevé et l'établissement de leur 'plan 5x30'. Le Comité de Nominations, de Gouvernance et de Durabilité de l'entreprise évaluera les candidats proposés par DOMA dans le cadre de leur processus de révision standard.
Le Conseil présentera sa recommandation formelle concernant les nominations de directeurs dans la prochaine déclaration de procuration définitive. Aucune action immédiate des actionnaires n'est requise, et la date de la Réunion Annuelle de 2025 n'a pas encore été annoncée. Evercore et Wachtell, Lipton, Rosen & Katz agissent respectivement en tant que conseillers financiers et juridiques.
Pacira BioSciences (PCRX) hat bestätigt, dass sie von DOMA Perpetual Capital Management Nominierungen für Direktoren für die Jahreshauptversammlung 2025 erhalten hat. DOMA hat drei Kandidaten zur Wahl für den Vorstand von Pacira vorgeschlagen.
Als Antwort erklärte Pacira, dass ihr Vorstand und das Managementteam Maßnahmen ergreifen, um den Aktionärswert zu steigern, einschließlich einer kürzlich abgeschlossenen umfassenden Portfolioüberprüfung und der Einführung ihres '5x30-Plans'. Das Nominierungs-, Governance- und Nachhaltigkeitskomitee des Unternehmens wird die von DOMA vorgeschlagenen Kandidaten im Rahmen ihres Standardprüfungsprozesses bewerten.
Der Vorstand wird seine formelle Empfehlung zu den Direktorennominierungen in der kommenden endgültigen Vollmachtsmitteilung präsentieren. Es sind keine sofortigen Maßnahmen der Aktionäre erforderlich, und das Datum der Jahreshauptversammlung 2025 wurde noch nicht bekannt gegeben. Evercore und Wachtell, Lipton, Rosen & Katz fungieren jeweils als Finanz- und Rechtsberater.
- Implementation of '5x30 plan' following comprehensive portfolio review
- Potential board disruption from activist investor DOMA's nomination of three directors
-- No Shareholder Action Required at This Time --
PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three candidates to stand for election to the Pacira Board of Directors (the “Board”) at the Company’s 2025 Annual Meeting of Stockholders.
Pacira issued the following statement in response to DOMA’s director nominations:
“Pacira’s Board and management team are taking decisive action to enhance shareholder value. We recently completed a comprehensive portfolio review and defined our 5x30 plan as the best plan to deliver shareholder value. The Nominating, Governance and Sustainability Committee of the Pacira Board will evaluate and consider DOMA’s proposed candidates, as it does with all director candidates.”
The Board will present its formal recommendation regarding director nominees in the Company’s definitive proxy statement and other materials, to be filed with the Securities and Exchange Commission and mailed to all shareholders eligible to vote at the 2025 Annual Meeting of Stockholders.
The date of the Annual Meeting has not yet been announced and shareholders are not required to take any action at this time.
Evercore is serving as financial advisor and Wachtell, Lipton, Rosen & Katz is serving as legal advisor to the Company.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
Forward-Looking Statements
Any statements in this document about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the 2025 Annual Meeting, ‘5x30’, Pacira’s growth and business strategy; Pacira’s future outlook, Pacira’s intellectual property and patent terms, Pacira’s growth and future operating results and trends, Pacira’s strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including Pacira’s plans with respect to the repayment of Pacira’s indebtedness, anticipated product portfolio, development programs, development of products, strategic alliances and other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. Pacira cannot assure you that its estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio; risks associated with acquisitions, such as the risk that the acquired businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; Pacira’s manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and Pacira’s business, including Pacira’s revenues, financial condition, cash flow and results of operations; the success of Pacira’s sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and Pacira’s ability to serve those markets; Pacira’s plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; Pacira’s plans to evaluate, develop and pursue additional product candidates utilizing Pacira’s proprietary multivesicular liposome (“pMVL”) drug delivery technology; the approval of the commercialization of Pacira’s products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; Pacira’s commercialization and marketing capabilities; Pacira’s ability to successfully complete capital projects; the outcome of any litigation; the recoverability of Pacira’s deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; the anticipated funding or benefits of Pacira’s share repurchase program; and factors discussed in the “Risk Factors” of Pacira’s most recent Annual Report on Form 10-K and in other filings that it periodically makes with the SEC. In addition, the forward-looking statements included in this document represent Pacira’s views as of the date of this document. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such Pacira anticipates that subsequent events and developments will cause its views to change. Except as required by applicable law, Pacira undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing Pacira’s views as of any date subsequent to the date of this document.
These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Pacira’s actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the “Risk Factors” of Pacira’s most recent Annual Report on Form 10-K and in other filings that Pacira periodically makes with the SEC.
Important Additional Information Regarding Proxy Solicitation
Pacira intends to file a proxy statement and BLUE proxy card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its solicitation of proxies for Pacira’s 2025 annual meeting of stockholders (the “2025 Proxy Statement,” and such meeting the “2025 Annual Meeting”). BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF PACIRA ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING PACIRA’S DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. These documents, including the definitive 2025 Proxy Statement (and any amendments or supplements thereto) and other documents filed by Pacira with the SEC, are, or will be when filed, available for no charge on the SEC’s website at http://www.sec.gov and on Pacira’s investor relations website at https://investor.pacira.com.
Participants in the Solicitation
Pacira, its directors, director nominees, certain of its executive officers and other employees may be deemed participants in the solicitation of proxies from stockholders in respect of the 2025 Annual Meeting. Information regarding the names of Pacira’s directors and executive officers and their respective interests in Pacira by security holdings or otherwise is set forth in Pacira’s proxy statement for the 2024 Annual Meeting of stockholders, filed with the SEC on April 22, 2024 (the “2024 Proxy Statement”). Please refer to the sections captioned “Director Compensation,” “Executive Compensation,” and “Stock Ownership Information” in the 2024 Proxy Statement. To the extent holdings of such participants in Pacira’s securities have changed since the amounts described in the 2024 Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership of Securities on Form 3 or Statements of Changes in Beneficial Ownership of Securities on Form 4 filed with the SEC: Form 4, filed by Jonathan Slonin on June 5, 2024; Form 4, filed by Daryl Gaugler on June 5, 2024; Form 4, filed by Kristen Williams on June 5, 2024; Form 4, filed by Lauren Riker on June 5, 2024; Form 4, filed by Mark A. Kronenfeld on June 13, 2024; Form 4, filed by Laura Brege on June 13, 2024; Form 4, filed by Kristen Williams on June 13, 2024; Form 4, filed by Alethia Young on June 13, 2024; Form 4, filed by Mark Froimson on June 13, 2024; Form 4, filed by Daryl Gaugler on June 13, 2024; Form 4, filed by Abraham Ceesay on June 13, 2024; Form 4, filed by Michael J. Yang on June 13, 2024; Form 4, filed by Marcelo Bigal on June 13, 2024; Form 4, filed by Christopher Christie on June 13, 2024; Form 4, filed by Jonathan Slonin on June 13, 2024; Form 4, filed by Lauren Riker on June 13, 2024; Form 4, filed by Jonathan Slonin on July 3, 2024; Form 4, filed by Daryl Gaugler on July 3, 2024; Form 4, filed by Jonathan Slonin on August 2, 2024; Form 4, filed by Marcelo Bigal on August 12, 2024; Form 4, filed by Mark Froimson on August 12, 2024; Form 4/A, filed by Marcelo Bigal on August 13, 2024; Form 4, filed by Frank D. Lee on August 13, 2024; Form 4, filed by Michael J. Yang on August 14, 2024; Form 4, filed by Laura Brege on August 19, 2024; Form 4, filed by Marcelo Bigal on August 19, 2024; Form 4, filed by Daryl Gaugler on September 13, 2024; Form 3, filed by Shawn Cross on October 23, 2024; Form 4, filed by Shawn Cross on November 5, 2024; Form 4, filed by Daryl Gaugler on December 16, 2024; Form 4, filed by Lauren Riker on January 6, 2025; Form 4, filed by Daryl Gaugler on January 6, 2025; Form 4, filed by Jonathan Slonin on January 6, 2025; Form 4, filed by Frank D. Lee on January 6, 2025; Form 3, filed by Brendan Teehan on January 28, 2025; Form 4, filed by Lauren Riker on February 4, 2025; Form 4, filed by Brendan Teehan on February 4, 2025; Form 4, filed by Frank D. Lee on February 4, 2025; Form 4, filed by Kristen Williams on February 4, 2025; and Form 4, filed by Jonathan Slonin on February 4, 2025. Additional information can also be found in Pacira’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 27, 2025. Details concerning potential participants in the solicitation, including Pacira’s director nominees for election at the 2025 Annual Meeting, will also be included in the 2025 Proxy Statement. These documents, including the definitive 2025 Proxy Statement (and any amendments or supplements thereto) and other documents filed by Pacira with the SEC, are, or will be when filed, available for no charge on the SEC’s website at http://www.sec.gov and on Pacira’s investor relations website at https://investor.pacira.com.
Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com Media Contact: Sara Marino, (973) 370-5430 sara.marino@pacira.com
FAQ
What is DOMA Perpetual's nomination proposal for Pacira BioSciences (PCRX)?
What strategic actions is Pacira BioSciences (PCRX) taking to enhance shareholder value?
When will Pacira (PCRX) shareholders need to vote on DOMA's board nominations?
Who are the advisors assisting Pacira (PCRX) with DOMA's nomination process?
